Pregnancy Outcome in Women with Mechanical Prosthetic Heart Valves.
Conditions
Interventions
Intervention 1: Intervention group: In this group, LMWH was administered subcutaneously as 1 mg/kg every 12 hours from the beginning of pregnancy until the end of the first 14 weeks, and then the pati
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: No drug allergy to any of the drugs studied No history of recurrent miscarriage or stillbirth associated with antiphospholipid syndrome Being monitored by the researcher from the beginning of pregnancy Having Class I or II heart disease Having a metal heart valve Having a pregnancy week of 14 weeks or less
Exclusion criteria
Exclusion criteria: Non-cooperation after inclusion Lack of access to the patient and follow-up Forced to terminate pregnancy immediately Warfarin use in the first 3 months Patients not able to follow up anti-10a factor Thrombocytopenia (less than 75,000)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maternal complications. Timepoint: After intervention. Method of measurement: Check list.;Fetal complications. Timepoint: After intervention. Method of measurement: Check list. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMinoo Movahedi
Esfahan University of Medical Sciences
Outcome results
None listed